← Back to Search

Intrauterine Device

Mirena Intrauterine System for Birth Control

Phase < 1
Waitlist Available
Research Sponsored by University of Oklahoma
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
18 years or older
desire an intrauterine device as postpartum contraception
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 1 year
Awards & highlights

Study Summary

This trial will compare the expulsion and discontinuation rates of postpartum intrauterine devices (IUDs) placed immediately after delivery versus IUDs placed during a follow-up visit.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Expulsion of intrauterine contraception
Secondary outcome measures
Discontinuation of intrauterine contraception

Trial Design

2Treatment groups
Experimental Treatment
Group I: Contraceptive MirenaExperimental Treatment1 Intervention
Determination of expulsion and discontinuation rates in participants randomly allocated to receive levonorgestrel intrauterine systems Mirena Intrauterine System
Group II: Contraceptive KyleenaExperimental Treatment1 Intervention
Determination of expulsion and discontinuation rates in participants randomly allocated to receive levonorgestrel intrauterine systems Kyleena Intrauterine System
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Levonorgestrel
FDA approved
Levonorgestrel
FDA approved

Find a Location

Who is running the clinical trial?

University of OklahomaLead Sponsor
455 Previous Clinical Trials
98,273 Total Patients Enrolled
Valorie Owens, MSWStudy DirectorUniversity of Oklahoma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~5 spots leftby Mar 2025